Evidence map›Paper›PMID 29491157›Full record

ArticleJournal of virology2018

Intragastric Administration of Lactobacillus plantarum and 2,2'-Dithiodipyridine-Inactivated Simian Immunodeficiency Virus (SIV) Does Not Protect Indian Rhesus Macaques from Intrarectal SIV Challenge or Reduce Virus Replication after Transmission.

Diane G Carnathan, Joseph J Mackel, Shelby L Sweat, Chiamaka A Enemuo, Etse H Gebru, Pallavi Dhadvai, Sailaja Gangadhara, Sakeenah Hicks, Thomas H Vanderford, Rama R Amara and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Diane G CarnathanEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Joseph J MackelEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Shelby L SweatEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Chiamaka A EnemuoEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Etse H GebruEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Pallavi DhadvaiEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Sailaja GangadharaEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Sakeenah HicksEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Thomas H VanderfordEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Rama R AmaraEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
José EsparzaInstitute for Human Virology, University of Maryland, Baltimore, Maryland, USA.
Wei LuInstitut de Recherche sur les Vaccins et l'Immunothérapie des Cancers et du SIDA, Université de Paris Descartes, Paris, France.
Jean-Marie AndrieuInstitut de Recherche sur les Vaccins et l'Immunothérapie des Cancers et du SIDA, Université de Paris Descartes, Paris, France.
Guido SilvestriEmory Vaccine Center, Emory University, Atlanta, Georgia, USA gsilves@emory.edu.
Emory University · USUniversité Paris Cité · FRUniversity of Maryland, Baltimore · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Joyce Kimberly Cohen · 2018 to 2026
$17.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI050409NIH HHS P51 OD011132NIH HHS U42 OD011023
6 · The paper itself

Abstract

A major obstacle to development of an effective AIDS vaccine is that along with the intended beneficial responses, the immunization regimen may activate CD4

Indexed as

2,2'-DipyridylAnimalsDisulfidesImmune ToleranceLactiplantibacillus plantarumMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccines, InactivatedVirus Replication2,2'-Dipyridyl2,2'-dipyridyl disulfideDisulfidesVaccines, Inactivatedoral vaccinesSIV vaccine

Identifiers

PMID29491157
PMCPMC5923080
OpenAlexW2792610649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.